;PMID: 3144694
;source_file_798.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..29] = [t:0..29]
;1)sentence:[e:34..105] = [t:34..105]
;2)section:[e:109..151] = [t:109..151]
;3)section:[e:155..268] = [t:155..268]
;4)sentence:[e:272..454] = [t:272..454]
;5)sentence:[e:455..538] = [t:455..538]
;6)sentence:[e:539..790] = [t:539..790]
;7)sentence:[e:791..926] = [t:791..926]
;8)sentence:[e:927..1214] = [t:927..1214]
;9)section:[e:1218..1262] = [t:1218..1262]

;section 0 Span:0..29
;Oncogene Res  1988;3(1):77-86
(SEC
  (FRAG (NNP:[0..8] Oncogene) (NNP:[9..12] Res) (CD:[14..18] 1988)
        (::[18..21] ;3-LRB-) (CD:[21..22] 1) (-RRB-:[22..23] -RRB-)
        (CD:[23..26] :77) (::[26..27] -) (CD:[27..29] 86)))

;sentence 1 Span:34..105
;Preferential and novel activation of H-ras in human bladder carcinomas.
;[71..76]:gene-rna:"H-ras"
;[86..104]:malignancy:"bladder carcinomas"
(SENT
  (NP-HLN
    (NP
      (ADJP (JJ:[34..46] Preferential) (CC:[47..50] and) (JJ:[51..56] novel))
      (NN:[57..67] activation))
    (PP (IN:[68..70] of)
      (NP (NN:[71..76] H-ras)))
    (PP-LOC (IN:[77..79] in)
      (NP (JJ:[80..85] human)
         (NN:[86..93] bladder) (NNS:[94..104] carcinomas)))
    (.:[104..105] .)))

;section 2 Span:109..151
;Visvanathan KV, Pocock RD, Summerhayes IC.
(SEC
  (FRAG (NNP:[109..120] Visvanathan) (NNP:[121..123] KV) (,:[123..124] ,)
        (NNP:[125..131] Pocock) (NNP:[132..134] RD) (,:[134..135] ,)
        (NNP:[136..147] Summerhayes) (NNP:[148..150] IC) (.:[150..151] .)))

;section 3 Span:155..268
;Department of Cell and Molecular Biology, Institute of Cancer Research,
;Chester  Beatty Laboratories, London, UK.
(SEC
  (FRAG (NNP:[155..165] Department) (IN:[166..168] of) (NNP:[169..173] Cell)
        (CC:[174..177] and) (NNP:[178..187] Molecular) (NNP:[188..195] Biology)
        (,:[195..196] ,) (NNP:[197..206] Institute) (IN:[207..209] of)
        (NNP:[210..216] Cancer) (NNP:[217..225] Research) (,:[225..226] ,)
        (NNP:[227..234] Chester) (NNP:[236..242] Beatty)
        (NNP:[243..255] Laboratories) (,:[255..256] ,) (NNP:[257..263] London)
        (,:[263..264] ,) (NNP:[265..268] UK.)))

;sentence 4 Span:272..454
;In a survey of primary human bladder carcinomas from 24 patients, using the 
;NIH/3T3 transfection nude mouse tumor assay, we have detected an activated 
;c-H-ras-1 gene in four cases.
;[287..319]:malignancy:"primary human bladder carcinomas"
;[425..434]:gene-rna:"c-H-ras-1"
(SENT
  (S
    (PP (IN:[272..274] In)
      (NP
        (NP (DT:[275..276] a) (NN:[277..283] survey))
        (PP (IN:[284..286] of)
          (NP
            (NP (JJ:[287..294] primary) (JJ:[295..300] human)
                (NN:[301..308] bladder) (NNS:[309..319] carcinomas))
            (PP (IN:[320..324] from)
              (NP (CD:[325..327] 24) (NNS:[328..336] patients)))))))
    (,:[336..337] ,)
    (S-ADV
      (NP-SBJ (-NONE-:[337..337] *))
      (VP (VBG:[338..343] using)
        (NP (DT:[344..347] the)
          (NML (NN:[349..352] NIH) (SYM:[352..353] /) (NN:[353..356] 3T3)
               (NN:[357..369] transfection))
          (NML (JJ:[370..374] nude) (NN:[375..380] mouse))
          (NN:[381..386] tumor) (NN:[387..392] assay))))
    (,:[392..393] ,)
    (NP-SBJ (PRP:[394..396] we))
    (VP (VBP:[397..401] have)
      (VP (VBN:[402..410] detected)
        (NP (DT:[411..413] an) (JJ:[414..423] activated)
            (NN:[425..434] c-H-ras-1) (NN:[435..439] gene))
        (PP (IN:[440..442] in)
          (NP (CD:[443..447] four) (NNS:[448..453] cases)))))
    (.:[453..454] .)))

;sentence 5 Span:455..538
;Two of these scored negative in primary  transfections using a NIH/3T3 focus
;assay.
(SENT
  (S
    (NP-SBJ
      (NP (CD:[455..458] Two))
      (PP (IN:[459..461] of)
        (NP (DT:[462..467] these))))
    (VP (VBD:[468..474] scored)
      (ADJP-CLR (JJ:[475..483] negative))
      (PP (IN:[484..486] in)
        (NP (JJ:[487..494] primary) (NNS:[496..509] transfections)))
      (S-MNR
        (NP-SBJ (-NONE-:[509..509] *))
        (VP (VBG:[510..515] using)
          (NP (DT:[516..517] a)
            (NML (NN:[518..521] NIH) (SYM:[521..522] /) (NN:[522..525] 3T3))
            (NN:[526..531] focus) (NN:[532..537] assay)))))
    (.:[537..538] .)))

;sentence 6 Span:539..790
;Oligonucleotide analysis of genomic  and enzymatically amplified DNA revealed
;substitution of valine at codon 12 in  DNA from three transfectants and their
;parental carcinomas, which was absent  from the DNA of normal tissue of each
;of these patients.
;[617..629]:variation-type:"substitution"
;[633..639]:variation-state-generic:"valine"
;[643..651]:variation-location:"codon 12"
;[695..714]:malignancy:"parental carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[539..554] Oligonucleotide) (NN:[555..563] analysis))
      (PP (IN:[564..566] of)
        (NP
          (NP (JJ:[567..574] genomic)
            (NML-2 (-NONE-:[574..574] *P*)))
          (CC:[576..579] and)
          (NP
            (ADJP (RB:[580..593] enzymatically) (JJ:[594..603] amplified))
            (NML-2 (NN:[604..607] DNA))))))
    (VP (VBD:[608..616] revealed)
      (NP
        (NP (NN:[617..629] substitution))
        (PP (IN:[630..632] of)
          (NP (NN:[633..639] valine))))
      (PP-LOC (IN:[640..642] at)
        (NP (NN:[643..648] codon) (CD:[649..651] 12)))
      (PP-LOC (IN:[652..654] in)
        (NP
          (NP
            (NP (NN:[656..659] DNA))
            (PP (IN:[660..664] from)
              (NP
                (NP (CD:[665..670] three) (NNS:[671..684] transfectants))
                (CC:[685..688] and)
                (NP (PRP$:[689..694] their)
                   (JJ:[695..703] parental) (NNS:[704..714] carcinomas)))))
          (,:[714..715] ,)
          (SBAR
            (WHNP-1 (WDT:[716..721] which))
            (S
              (NP-SBJ-1 (-NONE-:[721..721] *T*))
              (VP (VBD:[722..725] was)
                (ADJP-PRD (JJ:[726..732] absent)
                  (PP (IN:[734..738] from)
                    (NP
                      (NP (DT:[739..742] the) (NN:[743..746] DNA))
                      (PP (IN:[747..749] of)
                        (NP
                          (NP (JJ:[750..756] normal) (NN:[757..763] tissue))
                          (PP (IN:[764..766] of)
                            (NP
                              (NP (DT:[767..771] each))
                              (PP (IN:[772..774] of)
                                (NP (DT:[775..780] these)
                                    (NNS:[781..789] patients))))))))))))))))
    (.:[789..790] .)))

;sentence 7 Span:791..926
;The fourth activation  was identified as a cysteine substitution at codon 13,
;a novel activation of  c-H-ras-1 in a solid tumor sample.
;[834..842]:variation-state-generic:"cysteine"
;[843..855]:variation-type:"substitution"
;[859..867]:variation-location:"codon 13"
;[892..901]:gene-rna:"c-H-ras-1"
;[907..918]:malignancy:"solid tumor"
(SENT
  (S
    (NP-SBJ-1 (DT:[791..794] The) (JJ:[795..801] fourth)
              (NN:[802..812] activation))
    (VP (VBD:[814..817] was)
      (VP (VBN:[818..828] identified)
        (NP-1 (-NONE-:[828..828] *))
        (PP (IN:[829..831] as)
          (NP
            (NP
              (NP (DT:[832..833] a) (NN:[834..842] cysteine)
                  (NN:[843..855] substitution))
              (PP-LOC (IN:[856..858] at)
                (NP (NN:[859..864] codon) (CD:[865..867] 13))))
            (,:[867..868] ,)
            (NP
              (NP (DT:[869..870] a) (JJ:[871..876] novel)
                  (NN:[877..887] activation))
              (PP (IN:[888..890] of)
                (NP (NN:[892..901] c-H-ras-1)))
              (PP-LOC (IN:[902..904] in)
                (NP (DT:[905..906] a)
                   (JJ:[907..912] solid) (NN:[913..918] tumor)
                  (NN:[919..925] sample))))))))
    (.:[925..926] .)))

;sentence 8 Span:927..1214
;Thus, all seven activated ras genes reported  in human urothelial tumors
;(Fujita et al., Proc. Natl. Acad. Sci. USA 82,  3849-3853, 1985) have been
;c-H-ras-1 genes, strongly suggesting that this member  of the ras gene family
;is preferentially activated in cells of transitional  origin.
;[953..956]:gene-rna:"ras"
;[982..999]:malignancy:"urothelial tumors"
;[1075..1084]:gene-rna:"c-H-ras-1"
;[1137..1140]:gene-rna:"ras"
(SENT
  (S
    (ADVP (RB:[927..931] Thus))
    (,:[931..932] ,)
    (NP-SBJ
      (NP (DT:[933..936] all) (CD:[937..942] seven) (JJ:[943..952] activated)
          (NN:[953..956] ras) (NNS:[957..962] genes))
      (VP (VBN:[963..971] reported)
        (NP (-NONE-:[971..971] *))
        (PP-LOC (IN:[973..975] in)
          (NP (JJ:[976..981] human)
             (JJ:[982..992] urothelial) (NNS:[993..999] tumors)))
        (PRN (-LRB-:[1000..1001] -LRB-)
          (FRAG
            (NP (NNP:[1001..1007] Fujita) (FW:[1008..1010] et)
                (FW:[1011..1014] al.))
            (,:[1014..1015] ,)
            (NP (NNP:[1016..1021] Proc.) (NNP:[1022..1027] Natl.)
                (NNP:[1028..1033] Acad.) (NNP:[1034..1038] Sci.)
                (NNP:[1039..1042] USA))
            (FRAG (CD:[1043..1045] 82) (,:[1045..1046] ,) (CD:[1048..1052] 3849)
                  (HYPH:[1052..1053] -) (CD:[1053..1057] 3853)
                  (,:[1057..1058] ,) (CD:[1059..1063] 1985)))
          (-RRB-:[1063..1064] -RRB-))))
    (VP (VBP:[1065..1069] have)
      (VP (VBN:[1070..1074] been)
        (NP-PRD (NN:[1075..1084] c-H-ras-1) (NNS:[1085..1090] genes)))
      (,:[1090..1091] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1091..1091] *))
        (ADVP (RB:[1092..1100] strongly))
        (VP (VBG:[1101..1111] suggesting)
          (SBAR (IN:[1112..1116] that)
            (S
              (NP-SBJ-1
                (NP (DT:[1117..1121] this) (NN:[1122..1128] member))
                (PP (IN:[1130..1132] of)
                  (NP (DT:[1133..1136] the)
                    (NML (NN:[1137..1140] ras) (NN:[1141..1145] gene))
                    (NN:[1146..1152] family))))
              (VP (VBZ:[1153..1155] is)
                (ADVP (RB:[1156..1170] preferentially))
                (VP (JJ:[1171..1180] activated)
                  (NP-1 (-NONE-:[1180..1180] *))
                  (PP-LOC (IN:[1181..1183] in)
                    (NP
                      (NP (NNS:[1184..1189] cells))
                      (PP (IN:[1190..1192] of)
                        (NP (JJ:[1193..1205] transitional)
                            (NN:[1207..1213] origin))))))))))))
    (.:[1213..1214] .)))

;section 9 Span:1218..1262
;PMID: 3144694 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1218..1222] PMID) (::[1222..1223] :) (CD:[1224..1231] 3144694)
        (NN:[1232..1233] -LSB-) (NNP:[1233..1239] PubMed) (::[1240..1241] -)
        (NN:[1242..1249] indexed) (IN:[1250..1253] for)
        (NNP:[1254..1262] MEDLINE-RSB-)))
